Compare prices and buy Retatrutide + Cagrilintide Blend from 11 research peptide vendors - also called suppliers or sources. Updated daily.
A vendor-assembled mixture of retatrutide, Eli Lilly's investigational agonist of the GLP-1, GIP and glucagon receptors, and cagrilintide, Novo Nordisk's investigational long-acting amylin analog, with no CAS number of its own. No clinical trial has tested the two together, and the published human data on pairing cagrilintide with an incretin drug come from CagriSema, which combines it with semaglutide, so the pairing is a market convention rather than a pharmacological one. Retatrutide is the larger share, with the split varying by vendor, and the blend is sold for research use only.
For research purposes only. Not medical advice.
The retatrutide + cagrilintide blend puts two investigational peptides from two different drug companies in one vial. Retatrutide, Eli Lilly's LY3437943, is a single peptide that activates the GLP-1, GIP and glucagon receptors. Cagrilintide, from Novo Nordisk, is a long-acting analog of the pancreatic hormone amylin that acts at amylin and calcitonin receptors. Each has its own page for mechanism, trials and regulatory history, and both sit in the GLP agonist and weight loss category.
The blend is a mixture, so it has no CAS number of its own, and the names it is sold under are vendor branding that no pharmacopeia recognizes. It has no standard split either. In-stock listings in October 2026 state four, five, eight or ten parts retatrutide per part cagrilintide by mass, so retatrutide is the larger share in every vial indexed here.
The clinical case for giving an amylin analog with an incretin drug was built on other molecules. Novo Nordisk's CagriSema combines cagrilintide with semaglutide, a GLP-1 receptor agonist. In REDEFINE 1 (Garvey and colleagues, The New England Journal of Medicine, 2025), 3,417 adults with obesity or overweight and no diabetes were randomized to the combination, to either drug alone or to placebo. At 68 weeks mean body weight fell 20.4 percent with the combination and 3.0 percent with placebo, counting every participant randomized whether or not they stayed on treatment. The vendor blend that matches those two molecules is semaglutide + cagrilintide.
Eli Lilly, which develops retatrutide, has its own amylin receptor agonist, eloralintide, and is testing it with tirzepatide. Lilly reported Phase 2b results for that combination in September 2026 and registered a Phase 3 trial of a co-formulation in October 2026. Neither semaglutide nor tirzepatide is in this vial.
A search of ClinicalTrials.gov on October 20, 2026 found no registered study giving retatrutide with cagrilintide. None of retatrutide's registered studies includes an amylin analog, and none of cagrilintide's includes retatrutide.
The one published study of the pair is preclinical. Petersen and colleagues at the University of Copenhagen gave both drugs together to diet-induced obese male rats (Nature Metabolism, September 2026) and present the work as guidance for designing future single-molecule drugs that act on several receptors.
PeptideScouter has indexed this blend since April 2026, so vendors were selling the pair before that study appeared. No study in people has tested the combination, and the pairing in these vials is a market convention rather than a pharmacological one.
As of October 20, 2026, neither component holds an FDA approval, and no approved product combines them. Eli Lilly has said it plans to file for US approval of retatrutide in the first quarter of 2027. Novo Nordisk filed a New Drug Application for CagriSema in December 2025 and said in September 2026 that it expects a decision in the fourth quarter of 2026. That application covers cagrilintide only in combination with semaglutide.
The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition. Its warning letters to online sellers of both compounds state that, despite labels such as "for research use only", evidence from the sellers' own websites established that the products were intended as drugs for human use.
Vendor titles join a name or code for each component, usually with retatrutide first.
PeptideScouter records a blend's size as the vial's total peptide content. With retatrutide at 80 to about 91 percent of that mass, the blend's per-milligram figure mostly reflects retatrutide and compares only with a component-weighted average. Vials with different splits are not like-for-like. The tesamorelin + ipamorelin page explains the general case.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
Two investigational peptides from different companies in one vial: retatrutide, Eli Lilly's agonist of the GLP-1, GIP and glucagon receptors, and cagrilintide, Novo Nordisk's long-acting amylin analog. Retatrutide is the larger share in every split PeptideScouter indexes, from four to ten parts retatrutide per part cagrilintide in October 2026, and PeptideScouter records the combined total as the vial size. Because the blend is a mixture, it has no CAS number of its own, and a certificate of analysis that identifies and quantifies each component separately is the only check on what a vial holds. Material sold by research peptide vendors is offered for laboratory research use only and not for human consumption.
Not in people, as of October 20, 2026. ClinicalTrials.gov lists no registered study giving the two together. The only published study of the pair, by Petersen and colleagues in Nature Metabolism in September 2026, was in diet-induced obese male rats. The published human trial data on adding cagrilintide to an incretin drug come from CagriSema, Novo Nordisk's combination of cagrilintide with semaglutide, tested in the Phase 3 REDEFINE trials. Eli Lilly, which develops retatrutide, is testing its own amylin receptor agonist, eloralintide, with tirzepatide.
No. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide with semaglutide, a GLP-1 receptor agonist, and it is the combination tested in the Phase 3 REDEFINE trials. The vendor blend replaces semaglutide with retatrutide, an Eli Lilly compound that acts at the GLP-1, GIP and glucagon receptors, so CagriSema's trial results do not describe it. Vendors also sell a semaglutide + cagrilintide blend, which contains CagriSema's two molecules but is not the manufactured product either.
No. As of October 20, 2026, neither retatrutide nor cagrilintide holds an FDA approval, and no approved product combines them. Eli Lilly has said it plans to file for US approval of retatrutide in the first quarter of 2027. Novo Nordisk filed a New Drug Application for CagriSema in December 2025, and that application covers cagrilintide only in combination with semaglutide. The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law. The blend sold by research peptide vendors is offered for laboratory research use only and not for human consumption.
PeptideScouter records a blend's size as the total peptide in the vial, and retatrutide makes up 80 to about 91 percent of that total depending on the split. The per-milligram figure therefore mostly reflects retatrutide and compares only with an average of the two component prices weighted by the split. Two blend listings with different splits, such as four to one and ten to one, are not like-for-like, so the comparison holds only between listings with the same split.
Retatrutide + Cagrilintide Blend is sold by 11 research peptide vendors indexed on PeptideScouter, with 20 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 11 indexed research peptide vendors currently have Retatrutide + Cagrilintide Blend in stock. Stock state is refreshed daily from each vendor's catalog.
Glacier Aminos currently lists Retatrutide + Cagrilintide Blend at $3.12/mg, the lowest listed price across 11 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.81/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 11 vendors listing Retatrutide + Cagrilintide Blend publish a PeptideScouter code, worth 5% to 15% off. Applied, the lowest effective price falls from $3.12/mg listed to $2.81/mg at Glacier Aminos. Each vendor's code is shown beside its price in the table above.
Retatrutide + Cagrilintide Blend ranges from $3.12/mg to $11.90/mg across 20 listings from 11 research peptide vendors, normalized to USD per milligram and refreshed daily.
11 research peptide vendors currently list Retatrutide + Cagrilintide Blend on PeptideScouter. We track 20 listings across size and kit variants.
